PE20151905A1 - Formulacion farmaceutica en forma de comprimidos de dos capas que comprende inhibidor de hmg-coa reductasa e irbesartan - Google Patents

Formulacion farmaceutica en forma de comprimidos de dos capas que comprende inhibidor de hmg-coa reductasa e irbesartan

Info

Publication number
PE20151905A1
PE20151905A1 PE2015002384A PE2015002384A PE20151905A1 PE 20151905 A1 PE20151905 A1 PE 20151905A1 PE 2015002384 A PE2015002384 A PE 2015002384A PE 2015002384 A PE2015002384 A PE 2015002384A PE 20151905 A1 PE20151905 A1 PE 20151905A1
Authority
PE
Peru
Prior art keywords
irbesartan
coa reductase
reductase inhibitor
pharmaceutical formulation
hmg
Prior art date
Application number
PE2015002384A
Other languages
English (en)
Inventor
Young-Hun Kim
Jong Soo Woo
Young Jun Na
Yong Ii Kim
Jae Hyun Park
Min Jung Kim
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45395310&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151905(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Publication of PE20151905A1 publication Critical patent/PE20151905A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steering Devices For Bicycles And Motorcycles (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se presenta una formulacion farmaceutica en forma de comprimidos de dos fases que consiste en una primera fase que contiene irbesartan o sales aceptables desde el punto de vista farmaceutico de los anteriores y una segunda fase que contiene un inhibidor de HMG-CoA reductasa y un aditivo alcalino, que puede mejorar la velocidad de disolucion y la estabilidad de irbesartan y un inhibidor de HMG-CoA reductasa para potenciar la biodisponibilidad del farmaco cuando se compara con formulaciones complejas convencionales y para minimizar la generacion de los compuestos relacionados, de este modo usandose en forma efectiva como un agente terapeutico superior y estable para hipertension y la hipercolesterolemia
PE2015002384A 2010-05-14 2011-05-13 Formulacion farmaceutica en forma de comprimidos de dos capas que comprende inhibidor de hmg-coa reductasa e irbesartan PE20151905A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100045636 2010-05-14
KR1020100053782A KR101248804B1 (ko) 2010-05-14 2010-06-08 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제

Publications (1)

Publication Number Publication Date
PE20151905A1 true PE20151905A1 (es) 2016-01-07

Family

ID=45395310

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2012002144A PE20130204A1 (es) 2010-05-14 2011-05-13 Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan
PE2015002384A PE20151905A1 (es) 2010-05-14 2011-05-13 Formulacion farmaceutica en forma de comprimidos de dos capas que comprende inhibidor de hmg-coa reductasa e irbesartan

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2012002144A PE20130204A1 (es) 2010-05-14 2011-05-13 Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan

Country Status (36)

Country Link
US (1) US20130028974A1 (es)
EP (1) EP2568972B1 (es)
JP (1) JP5969466B2 (es)
KR (2) KR101248804B1 (es)
CN (1) CN103002883B (es)
AR (1) AR081032A1 (es)
AU (2) AU2011251085A1 (es)
BR (1) BR112012029064B8 (es)
CA (1) CA2798363C (es)
CL (1) CL2012003185A1 (es)
CO (1) CO6592025A2 (es)
CR (1) CR20120545A (es)
DK (1) DK2568972T3 (es)
DO (1) DOP2012000264A (es)
EA (1) EA023959B1 (es)
EC (1) ECSP12012224A (es)
ES (1) ES2645726T3 (es)
GT (1) GT201200309A (es)
HK (1) HK1181685A1 (es)
HU (1) HUE036638T2 (es)
IL (1) IL223012B (es)
JO (1) JO3409B1 (es)
MA (1) MA34313B1 (es)
MX (1) MX342868B (es)
MY (1) MY157307A (es)
NI (1) NI201200170A (es)
NZ (1) NZ604402A (es)
PE (2) PE20130204A1 (es)
PL (1) PL2568972T3 (es)
PT (1) PT2568972T (es)
SG (1) SG185778A1 (es)
SI (1) SI2568972T1 (es)
TW (1) TW201200166A (es)
UA (1) UA107967C2 (es)
WO (1) WO2011142621A2 (es)
ZA (1) ZA201209481B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103356500A (zh) * 2012-03-30 2013-10-23 肖广常 一种瑞舒伐他汀钙非诺贝特酸胆碱盐择时渗透泵控释片及其制备方法
BR102012020648A2 (pt) * 2012-08-17 2014-12-09 Hypermarcas S A Preparação farmacêutica oral sólida para a prevenção de doença cardio e cerebrovasculares e comprimido
KR20140028971A (ko) 2012-08-31 2014-03-10 한미약품 주식회사 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
KR20140030505A (ko) * 2012-08-31 2014-03-12 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
ES2747098T3 (es) * 2013-03-14 2020-03-10 Boryung Pharm Fármaco de combinación farmacéutica
KR101597004B1 (ko) * 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
KR20150079373A (ko) * 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
KR101771766B1 (ko) * 2013-12-30 2017-08-28 알보젠코리아 주식회사 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제
CN105769793A (zh) * 2016-04-04 2016-07-20 孙爱华 一种辛伐他汀片剂及其制备方法
KR102465736B1 (ko) * 2018-12-31 2022-11-11 주식회사 보령 정제 및 이의 제조방법
KR102042626B1 (ko) * 2019-06-26 2019-11-11 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
WO2022260439A1 (ko) * 2021-06-09 2022-12-15 주식회사 보령 약학적 복합 제제 및 제조 방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
JP2003073270A (ja) * 2001-08-30 2003-03-12 Nisshin Seiyaku Kk 安定性および溶出性の良好なプラバスタチンナトリウム錠
DK1854454T3 (da) * 2002-01-16 2014-01-13 Boehringer Ingelheim Pharma Fremgangsmåde til fremstilling af amorf telmisartan
EP1515701B1 (en) * 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US20060078615A1 (en) * 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin
EP1853249A2 (en) * 2005-02-10 2007-11-14 LifeCycle Pharma A/S A stable pharmaceutical composition comprising a fixed dose combination of fenofibrate and an hmg-coa reductase inhibitor
CA2625646A1 (en) * 2005-10-25 2007-05-03 Merck & Co., Inc. Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension
WO2008010008A2 (en) * 2006-07-17 2008-01-24 Wockhardt Limited Cardiovascular combinations using rennin-angiotensin inhibitors
EP2086519B1 (en) * 2006-10-30 2017-06-21 HanAll Biopharma Co., Ltd. Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors
WO2008068217A2 (en) * 2006-12-04 2008-06-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system
WO2009134057A2 (ko) * 2008-04-29 2009-11-05 한올제약주식회사 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
KR20090114190A (ko) * 2008-04-29 2009-11-03 한올제약주식회사 방출성이 제어된 ＨＭＧ―ＣｏＡ 환원 효소 억제제와안지오텐신―Ⅱ―수용체 차단제의 복합 조성물
KR20090114326A (ko) * 2008-04-29 2009-11-03 한올제약주식회사 약제학적 제제
CN101590231A (zh) * 2008-05-29 2009-12-02 北京奥萨医药研究中心有限公司 血管紧张素ⅱ受体拮抗剂、他汀类降脂药和烟酸的药物组合物及其用途
CZ2008740A3 (cs) * 2008-11-24 2010-01-06 Zentiva, A.S. Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem

Also Published As

Publication number Publication date
TW201200166A (en) 2012-01-01
SI2568972T1 (sl) 2017-10-30
MX2012013175A (es) 2013-01-17
BR112012029064B8 (pt) 2020-08-11
ES2645726T3 (es) 2017-12-07
JP2013526516A (ja) 2013-06-24
WO2011142621A3 (en) 2012-03-08
PE20130204A1 (es) 2013-03-11
WO2011142621A2 (en) 2011-11-17
PL2568972T3 (pl) 2017-12-29
US20130028974A1 (en) 2013-01-31
NI201200170A (es) 2013-05-29
JP5969466B2 (ja) 2016-08-17
EP2568972A2 (en) 2013-03-20
HK1181685A1 (zh) 2013-11-15
CL2012003185A1 (es) 2013-02-22
DOP2012000264A (es) 2012-11-30
GT201200309A (es) 2014-03-14
CA2798363C (en) 2018-06-05
IL223012A0 (en) 2013-02-03
IL223012B (en) 2019-03-31
ZA201209481B (en) 2014-02-26
EP2568972A4 (en) 2014-07-02
BR112012029064B1 (pt) 2019-10-22
EA023959B1 (ru) 2016-07-29
CR20120545A (es) 2012-12-06
HUE036638T2 (hu) 2018-07-30
DK2568972T3 (da) 2017-11-06
ECSP12012224A (es) 2012-11-30
MX342868B (es) 2016-10-17
CA2798363A1 (en) 2011-11-17
EP2568972B1 (en) 2017-08-02
AR081032A1 (es) 2012-05-30
CN103002883B (zh) 2015-08-26
KR20130024940A (ko) 2013-03-08
MY157307A (en) 2016-05-31
KR101248804B1 (ko) 2013-03-29
AU2011251085A1 (en) 2013-01-10
CO6592025A2 (es) 2013-01-02
AU2016203739B2 (en) 2017-11-02
KR20110126020A (ko) 2011-11-22
BR112012029064A2 (pt) 2016-08-09
NZ604402A (en) 2015-02-27
PT2568972T (pt) 2017-10-09
MA34313B1 (fr) 2013-06-01
CN103002883A (zh) 2013-03-27
EA201291247A1 (ru) 2013-04-30
SG185778A1 (en) 2013-01-30
UA107967C2 (en) 2015-03-10
JO3409B1 (ar) 2019-10-20
AU2016203739A1 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
PE20151905A1 (es) Formulacion farmaceutica en forma de comprimidos de dos capas que comprende inhibidor de hmg-coa reductasa e irbesartan
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
CY1118292T1 (el) Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων
EA201071204A1 (ru) Применение дронедарона для приготовления лекарственного средства для применения в предотвращении госпитализации в кардиологическое отделение или смертности
ECSP13012812A (es) Formulaciones inmunosupresoras
AR089666A1 (es) Formulacion farmaceutica estable para administracion oral que comprende levocetirizina o una de sus sales aceptables desde el punto de vista farmaceutico, y montelukast o una de sus sales aceptables desde el punto de vista farmaceutico
PH12015501386A1 (en) Tricyclic compounds
CO7350622A2 (es) Formulación de una cápsula farmacéutica compuesta que comprende irbesartan e inhibidor de la hmg-coa reductasa
MX359436B (es) Preparacion de combinacion farmaceutica que comprende un inhibidor de hmg-coa reductasa y un inhibidor de la absorcion de colesterol.
MX2013001279A (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
NI201500027A (es) Formulación de comprimidos compuestos de dos fases que comprenden atorvastatina, irbesartan y carbonato de magnesio.
CL2008003584A1 (es) Uso de la 10-[(3r)-1-azabiciclo]oct-3-ilmetil]-10-h-fenotiazina, o una de sus sales farmaceuticamente aceptables para la preparación de un medicamento util para prevenir o tratar la bronconeumopatia obstructiva.
TH126521A (th) สูตรทางเภสัชกรรมในรูปยาเม็ดสองชั้นที่ประกอบรวมด้วย hmg-coaรีดัคเทส อินฮิบิเตอร์ และเออร์เบซาร์แทน
TR201005911A2 (tr) Geliştirilmiş dissolüsyon profiline sahip bir ilaç formülasyonu.
Pathan Synthesis and pharmacological activity of bicyclic heterocycles
DOP2011000238A (es) Nueva asociacion de ingredientes activos que contienen un farmaco antinflamatorio, no esteroideo y un derivado de colchicosido
CR20110394A (es) Nueva asociacion de ingredientes activos que contienen un farmaco antiinflamatorio, no esteroideo y un derivado de colchicosido
AR047700A1 (es) Composicion farmaceutica para la liberacion mejorada de diclofenac
MX352778B (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
CO6280050A1 (es) Forma farmaceutica de inhibidores de la fosfodiesterasa para administracion transmucosa

Legal Events

Date Code Title Description
FD Application declared void or lapsed